Intervention Review

You have free access to this content

Transdermal fentanyl for cancer pain

  1. Gina Hadley1,*,
  2. Sheena Derry2,
  3. R Andrew Moore2,
  4. Philip J Wiffen2

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 5 OCT 2013

Assessed as up-to-date: 3 SEP 2013

DOI: 10.1002/14651858.CD010270.pub2


How to Cite

Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010270. DOI: 10.1002/14651858.CD010270.pub2.

Author Information

  1. 1

    University of Oxford, Pain Research and Nuffield Department of Clinical Neurosciences, Oxford, Oxfordshire, UK

  2. 2

    University of Oxford, Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), Oxford, Oxfordshire, UK

*Gina Hadley, Pain Research and Nuffield Department of Clinical Neurosciences, University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, UK. glhadley@doctors.org.uk.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 5 OCT 2013

SEARCH

[Figure 1]
Figure 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Fentanyl versus sustained release morphine, outcome: 1.1 Constipation.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Fentanyl versus sustained release morphine, Outcome 1 Constipation.